Cambridge Investment Research Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 127,249 shares of RXRX stock, worth $702,414. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,249
Previous 117,120
8.65%
Holding current value
$702,414
Previous $620,000
3.87%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding RXRX
# of Institutions
367Shares Held
288MCall Options Held
7.76MPut Options Held
6.19M-
Vanguard Group Inc Valley Forge, PA36.1MShares$199 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33MShares$182 Million1.38% of portfolio
-
Baillie Gifford & CO24.2MShares$133 Million0.1% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$95.6 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$81 Million0.31% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $996M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...